Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 known ✓ | P04062 | 1/20 | 0.35 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL29697295 | 1.00 | MEN1 (0.55) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL5257688 | 1.00 | MEN1 (0.55) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL4258138 | 0.98 | MEN1 (0.52) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL9581035 | 0.98 | MEN1 (0.52) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL27453848 | 0.98 | MEN1 (0.52) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL21246910 | 0.98 | CYP3A4 (0.59) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL188002 | 0.92 | LMNA (0.46) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL2586847 | 0.92 | LMNA (0.46) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL8167949 | 0.92 | LMNA (0.46) | MEN1LMNAKMT2ACYP3A4SLC5A7 | |
| Cadaverine Tartrate SCHEMBL5311459 | 0.92 | LMNA (0.46) | MEN1LMNAKMT2ACYP3A4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160830-A1 | COMPOSITIONS COMPRISING CHOLINE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2022-05-26 | — | — | US | disclosed |
| US-11278591-B2 | Compositions comprising choline | BALCHEM CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088404-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS , INC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | SHH, GLI1, SMO | GBA1 1873/4885ADRA2A 3761/4885ADRA1A 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.